Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.49 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.49 |
| ▸ | DNPEP | Q9ULA0 | 3/20 | 0.49 |
| ▸ | ALPI | P09923 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | XIAP | P98170 | 1/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | LAP3 | P28838 | 3/20 | 0.42 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2214633 | 1.00 | ANPEP (0.49) | ANPEPRNPEPDNPEPALPIPKM | |
| SCHEMBL2215767 | 0.89 | ANPEP (0.53) | ANPEPRNPEPDNPEPALPIPKM | |
| SCHEMBL19361331 | 0.89 | ANPEP (0.56) | ANPEPRNPEPDNPEPALPIPKM | |
| SCHEMBL2762134 | 0.82 | ALOX15 (0.56) | ANPEPRNPEPDNPEPALPIPKM | |
| SCHEMBL2762133 | 0.82 | ALOX15 (0.56) | ANPEPRNPEPDNPEPALPIPKM | |
| SCHEMBL15844573 | 0.82 | ANPEP (0.47) | ANPEPRNPEPDNPEPALPIPKM | |
| SCHEMBL15844571 | 0.82 | ANPEP (0.47) | ANPEPRNPEPDNPEPALPIPKM | |
| Phenylalanine SCHEMBL2214641 | 0.80 | SLC7A5 (0.59) | ANPEPRNPEPDNPEPALPIPKM | |
| SCHEMBL14095409 | 0.80 | ALPI (0.61) | ANPEPALPIPKMPTGS1XIAP | |
| SCHEMBL6368998 | 0.80 | ALPI (0.61) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2018-11-01 | — | — | US | claimed |
| US-20170182131-A9 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2017-06-29 | — | — | US | claimed |
| EP-2741765-B9 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2016-09-28 | — | — | EP | claimed |
| EP-2741765-B1 | INJECTABLE SOLUTION OF AT LEAST ONE TYPE OF BASAL INSULIN | ADOCIA (FR) | 2016-03-30 | — | — | EP | claimed |
| US-20150250858-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2015-09-10 | — | — | US | claimed |
| US-9089476-B2 | Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2015-07-28 | — | — | US | claimed |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2013-03-14 | — | — | US | claimed |
| US-20230255202-A1 | ANTIMICROBIAL COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2023-08-17 | — | — | US | disclosed |
| US-20230255202-A1 | ANTIMICROBIAL COMPOSITION | THE PROCTER & GAMBLE COMPANY | 2023-08-17 | — | — | US | disclosed |
| EP-4226767-A1 | ANTIMICROBIAL COMPOSITION | The Procter & Gamble Company (US) | 2023-08-16 | — | — | EP | disclosed |
| US-10449256-B2 | Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer | ADOCIA (FR) | 2019-10-22 | — | — | US | disclosed |
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | ADOCIA (FR) | 2018-11-01 | — | — | US | disclosed |
| US-20180169249-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER | ADOCIA (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9089476-B2 | Injectable solution at pH 7 comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2015-07-28 | — | — | US | disclosed |
| US-20140249079-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANONIC POLYMER | ADOCIA (FR) | 2014-09-04 | — | — | US | disclosed |
| US-20130245246-A1 | POLYSACCHARIDES COMPRISING CARBOXYL FUNCTIONAL GROUPS SUBSTITUTED BY A HYDROPHOBIC ALCOHOL DERIVATIVE | ADOCIA (FR) | 2013-09-19 | — | — | US | disclosed |
| US-8426382-B2 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative | ADOCIA (FR) | 2013-04-23 | — | — | US | disclosed |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | ADOCIA (FR) | 2013-03-14 | — | — | US | disclosed |
| US-20110178011-A1 | Polysaccharide/BMP complexes which are soluble at physiological pH | ADOCIA (FR) | 2011-07-21 | — | — | US | disclosed |
| US-20100305035-A1 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative | ADOCIA (FR) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170182131-A9 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | ANPEP 825/4885RNPEP 1773/4885DNPEP 171/4885 |
| US-20230255202-A1 | ANTIMICROBIAL COMPOSITION | ARG1, CUTA, SLC7A1 | ANPEP 66/4885RNPEP 691/4885DNPEP 307/4885 |
| US-20130245246-A1 | POLYSACCHARIDES COMPRISING CARBOXYL FUNCTIONAL GROUPS SUBSTITUTED BY A HYDROPHOBIC ALCOHOL DERIVATIVE | CD44, B3GAT3, UGCG | ANPEP 3272/4885RNPEP 4341/4885DNPEP 3844/4885 |
| US-20180311316-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | ANPEP 825/4885RNPEP 1773/4885DNPEP 171/4885 |
| US-20100305035-A1 | Polysaccharides comprising carboxyl functional groups substituted by a hydrophobic alcohol derivative | CD44, ADH1C, ADH5 | ANPEP 134/4885RNPEP 1399/4885DNPEP 339/4885 |
| US-20150250858-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN WHOSE PI IS BETWEEN 5.8 AND 8.5 | IAPP, IGFBP5, INSR | ANPEP 825/4885RNPEP 1773/4885DNPEP 171/4885 |
| US-20180169249-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANIONIC POLYMER | IAPP, IGFBP5, IDE | ANPEP 151/4885RNPEP 788/4885DNPEP 121/4885 |
| US-10449256-B2 | Injectable solution at pH 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer | IAPP, IGFBP5, IDE | ANPEP 151/4885RNPEP 788/4885DNPEP 121/4885 |
| US-20130065826-A1 | Injectable solution at pH 7 Comprising at least one basal insulin whose PI is between 5.8 and 8.5 | IAPP, IGFBP5, INSR | ANPEP 825/4885RNPEP 1773/4885DNPEP 171/4885 |
| US-20140249079-A1 | INJECTABLE SOLUTION AT PH 7 COMPRISING AT LEAST ONE BASAL INSULIN THE ISOELECTRIC POINT OF WHICH IS BETWEEN 5.8 AND 8.5 AND A HYDROPHOBIZED ANONIC POLYMER | IAPP, IGFBP5, IDE | ANPEP 77/4885RNPEP 699/4885DNPEP 69/4885 |
| US-20110178011-A1 | Polysaccharide/BMP complexes which are soluble at physiological pH | BMP1, BMP2, BMP6 | ANPEP 628/4885RNPEP 922/4885DNPEP 1318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.